Showing results (171-180 of 262) with videos related to

Sort By:
Pageof 27
Genome Medicine|June 30, 2025
The CXCL16/CXCR6 axis is linked to immune effector cell-associated neurotoxicity in chimeric antigen receptor (CAR) T cell therapyI-Na Lu, Louisa Müller-Miny, Carolin Krekeler, et al.
Translational Oncology|August 21, 2018
Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue SarcomaTorsten Kessler, Ariane Baumeier, Caroline Brand, et al.
Oncotarget|October 15, 2016
Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarctionJanine Stucke-Ring, Julian Ronnacker, Caroline Brand, et al.
Plos Pathogens|October 15, 2024
Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infectionMichael Schoefbaenker, Theresa Günther, Eva Ulla Lorentzen, et al.
Leukemia|February 16, 2020
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphomaGeorg Lenz, Eliza Hawkes, Gregor Verhoef, et al.
Annals of Hematology|November 18, 2022
A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapyAndrew F Berdel, Raphael Koch, Joachim Gerss, et al.
Blood|June 9, 2023
BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosisAnja Schmitt, Melanie Grimm, Nina Kreienkamp, et al.
British Journal of Haematology|February 23, 2018
High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemiaNina K Steckel, Christoph Groth, Jan-Henrik Mikesch, et al.
Annals of Hematology|March 24, 2019
Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)Torsten Kessler, Steffen Koschmieder, Christoph Schliemann, et al.
Investigational New Drugs|March 16, 2020
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Pageof 27